Last week, three insiders from Maiden Holdings, Ltd. (MHLD) filed Form 4s disclosing the purchase of 380,000 shares at an average price of $0.78 per share. An interesting cluster of buying. But here's what's astonishing -- just seven months earlier the stock traded at $8.75.
Billionaire Mori Arkin filed a 13D on Aclaris Therapeutics (ACRS), a development stage microcap biotech company with a promising treatment for common warts. Arkin bought the shares through his personal partnership, "The 1999 Company." In the activist filing he disclosed the following trades: Purchase/SaleSharesPriceDate Running ...
Lottery ticket stocks are equities perceived by investors to provide a small chance of a huge payoff. Like playing the lottery, many investors find these stocks -- usually low-priced, thinly traded with little or no earnings -- very alluring. However, studies show that -- like the...
Twenty-two minutes after regular market hours closed on July 2, an Orbimed Advisors Form 4 relating to Corvus Pharmaceuticals Inc (CRVS) was posted on the SEC's website. The hedge fund, a 10%+ holder and insider in CRVS, disclosed that between June 27 and July 1 it...
A three day (dead cat?) bounce propelled the S&P 500 over 13% higher last week, rescuing stocks, at least temporarily, from the worst stretch of performance since the dark days of 1929. During the Coronavirus crash over the last several weeks, stocks were liquidated indiscriminately, as investors...
Hedge fund managers with hundreds of millions of dollars rarely buy the illiquid shares of a micro-cap company -- but when they do it's often a prelude to much higher prices for that stock. Below I discuss the 13F "secret" to uncovering micro-cap winners as the "Whales"...
Perceptive Advisors' Neptune Wellness Solutions (NEPT) position increased by 50% during the 3rd quarter of 2019, to 4.5 million shares. The stake represents 14.53% of the Cannabis extraction company's outstanding shares. NEPT was Perceptive Advisors' #20 position at Q3 close. The increase in Perceptive'...
Obscure stocks -- publicly traded, unknown, hidden companies with little or even no analyst coverage -- may not seem like good investments. Seriously, who wants to invest in a stock no one has ever heard of? Some of the top hedge fund managers in the world, that's...
Replicating Baker Brothers holdings, using 13F filings submitted quarterly by the life sciences hedge fund, has been an awesome strategy over the years. But by focusing on the smaller stocks owned by the fund, returns were even better. Baker Bros Advisors LP, with $17.33...
The January Effect and insider trading anomaly can combine for unusually profitable opportunities. As year-end approaches, it's a great time to scan the universe of equities for oversold, cheap stocks being accumulated by insiders. The January Effect refers to the tendency for stock prices -- especially...